Kailera Therapeutics Other Non-Current Liabilities decreased by 25.6% to $201.00K in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
An increase may indicate rising long-term operational risks or deferred tax burdens, while a decrease suggests the settlement of these obligations.
This represents miscellaneous long-term obligations that do not fit into standard categories like long-term debt or pens...
Peers in the medical device and pharmaceutical sectors often hold similar balances related to deferred tax liabilities and long-term environmental or legal accruals.
other_non_current_liabilities| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $270.00K | $201.00K |
| QoQ Change | — | -25.6% |